The Pall Suporlife CDF CHS92DPDDL is a high-performance, dual-port, dead-end filter that is designed for use in a variety of applications, including biopharmaceutical manufacturing, bioprocessing, and medical device manufacturing. The filter features a 0.22-micron nominal pore size and a 99.999% (0.001%) bacterial retention efficiency, making it ideal for removing bacteria, viruses, and other particulate matter from fluids. The filter is also resistant to a wide range of chemicals and solvents, making it suitable for use in a variety of harsh environments.
Here are some of the key features of the Pall Suporlife CDF CHS92DPDDL:
- High-performance filtration: 0.22-micron nominal pore size and 99.999% (0.001%) bacterial retention efficiency
- Dual-port design: for easy loading and unloading of filters
- Dead-end filtration: for maximum filtration efficiency
- Chemical and solvent resistance: for use in a variety of harsh environments
- Long filter life: up to 12 months
The Pall Suporlife CDF CHS92DPDDL is a reliable and versatile filter that can be used in a variety of demanding applications. It is a valuable tool for ensuring the quality and safety of fluids in the biopharmaceutical, bioprocessing, and medical device industries.
Here are some additional benefits of using the Pall Suporlife CDF CHS92DPDDL:
- Reduced risk of contamination: The high-efficiency filtration removes bacteria, viruses, and other particulate matter from fluids, reducing the risk of contamination.
- Improved product quality: The consistent filtration performance ensures that the quality of products is maintained.
- Increased process uptime: The long filter life minimizes downtime and increases productivity.
- Reduced operating costs: The low maintenance requirements and long filter life save money in the long run.
If you are looking for a high-performance, reliable, and versatile filter for your biopharmaceutical, bioprocessing, or medical device applications, the Pall Suporlife CDF CHS92DPDDL is a great option.
Reviews
There are no reviews yet.